首页 > 最新文献

Clinical Microbiology Reviews最新文献

英文 中文
The human microbiome in space: parallels between Earth-based dysbiosis, implications for long-duration spaceflight, and possible mitigation strategies. 太空中的人类微生物群:地球上菌群失调的相似之处、对长期太空飞行的影响以及可能的缓解策略。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-09-12 Epub Date: 2024-08-13 DOI: 10.1128/cmr.00163-22
Sofia Etlin, Julianna Rose, Luca Bielski, Claire Walter, Ashley S Kleinman, Christopher E Mason

SUMMARYThe human microbiota encompasses the diverse communities of microorganisms that reside in, on, and around various parts of the human body, such as the skin, nasal passages, and gastrointestinal tract. Although research is ongoing, it is well established that the microbiota exert a substantial influence on the body through the production and modification of metabolites and small molecules. Disruptions in the composition of the microbiota-dysbiosis-have also been linked to various negative health outcomes. As humans embark upon longer-duration space missions, it is important to understand how the conditions of space travel impact the microbiota and, consequently, astronaut health. This article will first characterize the main taxa of the human gut microbiota and their associated metabolites, before discussing potential dysbiosis and negative health consequences. It will also detail the microbial changes observed in astronauts during spaceflight, focusing on gut microbiota composition and pathogenic virulence and survival. Analysis will then turn to how astronaut health may be protected from adverse microbial changes via diet, exercise, and antibiotics before concluding with a discussion of the microbiota of spacecraft and microbial culturing methods in space. The implications of this review are critical, particularly with NASA's ongoing implementation of the Moon to Mars Architecture, which will include weeks or months of living in space and new habitats.

摘要人体微生物群包括居住在人体各部位(如皮肤、鼻腔和胃肠道)内、上和周围的各种微生物群落。尽管研究仍在继续,但微生物群通过产生和改变代谢物和小分子对人体产生重大影响的观点已得到公认。微生物群组成的紊乱--菌群失调--也与各种不良健康后果有关。随着人类开始执行更长时间的太空任务,了解太空旅行的条件如何影响微生物群,进而影响宇航员的健康非常重要。本文将首先描述人类肠道微生物群的主要分类群及其相关代谢物的特征,然后讨论潜在的菌群失调和对健康的负面影响。文章还将详细介绍宇航员在太空飞行期间观察到的微生物变化,重点是肠道微生物群的组成以及致病菌的毒力和存活率。然后将分析如何通过饮食、运动和抗生素保护宇航员的健康免受不利微生物变化的影响,最后讨论航天器微生物群和太空微生物培养方法。这篇综述的影响至关重要,尤其是美国国家航空航天局正在实施的 "从月球到火星架构"(Moon to Mars Architecture),其中将包括数周或数月的太空生活和新的栖息地。
{"title":"The human microbiome in space: parallels between Earth-based dysbiosis, implications for long-duration spaceflight, and possible mitigation strategies.","authors":"Sofia Etlin, Julianna Rose, Luca Bielski, Claire Walter, Ashley S Kleinman, Christopher E Mason","doi":"10.1128/cmr.00163-22","DOIUrl":"10.1128/cmr.00163-22","url":null,"abstract":"<p><p>SUMMARYThe human microbiota encompasses the diverse communities of microorganisms that reside in, on, and around various parts of the human body, such as the skin, nasal passages, and gastrointestinal tract. Although research is ongoing, it is well established that the microbiota exert a substantial influence on the body through the production and modification of metabolites and small molecules. Disruptions in the composition of the microbiota-dysbiosis-have also been linked to various negative health outcomes. As humans embark upon longer-duration space missions, it is important to understand how the conditions of space travel impact the microbiota and, consequently, astronaut health. This article will first characterize the main taxa of the human gut microbiota and their associated metabolites, before discussing potential dysbiosis and negative health consequences. It will also detail the microbial changes observed in astronauts during spaceflight, focusing on gut microbiota composition and pathogenic virulence and survival. Analysis will then turn to how astronaut health may be protected from adverse microbial changes via diet, exercise, and antibiotics before concluding with a discussion of the microbiota of spacecraft and microbial culturing methods in space. The implications of this review are critical, particularly with NASA's ongoing implementation of the Moon to Mars Architecture, which will include weeks or months of living in space and new habitats.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
mRNA-based HIV-1 vaccines. 基于 mRNA 的 HIV-1 疫苗。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-09-12 Epub Date: 2024-07-17 DOI: 10.1128/cmr.00041-24
Shamim Ahmed, Alon Herschhorn

SUMMARYThe success of the Severe Acute Respiratory Syndrome Coronavirus 2 mRNA vaccines to lessen/prevent severe COVID-19 opened new opportunities to develop RNA vaccines to fight other infectious agents. HIV-1 is a lentivirus that integrates into the host cell genome and persists for the lifetime of infected cells. Multiple mechanisms of immune evasion have posed significant obstacles to the development of an effective HIV-1 vaccine over the last four decades since the identification of HIV-1. Recently, attempts to address some of these challenges have led to multiple studies that manufactured, optimized, and tested, in different animal models, mRNA-based HIV-1 vaccines. Several clinical trials have also been initiated or are planned to start soon. Here, we review the current strategies applied to HIV-1 mRNA vaccines, discuss different targeting approaches, summarize the latest findings, and offer insights into the challenges and future of HIV-1 mRNA vaccines.

摘要 严重急性呼吸系统综合征冠状病毒 2 mRNA 疫苗在减轻/预防严重 COVID-19 方面取得了成功,这为开发 RNA 疫苗以对抗其他传染病病原体提供了新的机遇。HIV-1 是一种慢病毒,可整合到宿主细胞基因组中,并在受感染细胞的整个生命周期中持续存在。自发现 HIV-1 以来的 40 年中,多种免疫逃避机制对开发有效的 HIV-1 疫苗构成了重大障碍。最近,为了应对其中的一些挑战,人们开展了多项研究,制造、优化并在不同动物模型中测试基于 mRNA 的 HIV-1 疫苗。一些临床试验也已经启动或计划很快启动。在此,我们回顾了目前应用于 HIV-1 mRNA 疫苗的策略,讨论了不同的靶向方法,总结了最新发现,并对 HIV-1 mRNA 疫苗面临的挑战和未来提出了见解。
{"title":"mRNA-based HIV-1 vaccines.","authors":"Shamim Ahmed, Alon Herschhorn","doi":"10.1128/cmr.00041-24","DOIUrl":"10.1128/cmr.00041-24","url":null,"abstract":"<p><p>SUMMARYThe success of the Severe Acute Respiratory Syndrome Coronavirus 2 mRNA vaccines to lessen/prevent severe COVID-19 opened new opportunities to develop RNA vaccines to fight other infectious agents. HIV-1 is a lentivirus that integrates into the host cell genome and persists for the lifetime of infected cells. Multiple mechanisms of immune evasion have posed significant obstacles to the development of an effective HIV-1 vaccine over the last four decades since the identification of HIV-1. Recently, attempts to address some of these challenges have led to multiple studies that manufactured, optimized, and tested, in different animal models, mRNA-based HIV-1 vaccines. Several clinical trials have also been initiated or are planned to start soon. Here, we review the current strategies applied to HIV-1 mRNA vaccines, discuss different targeting approaches, summarize the latest findings, and offer insights into the challenges and future of HIV-1 mRNA vaccines.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Staphylococcus capitis: insights into epidemiology, virulence, and antimicrobial resistance of a clinically relevant bacterial species. 头癣葡萄球菌:对一种临床相关细菌的流行病学、毒性和抗菌药耐药性的深入研究。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-09-12 Epub Date: 2024-06-20 DOI: 10.1128/cmr.00118-23
Deborah M Crepin, Marie Chavignon, Paul O Verhoeven, Frédéric Laurent, Jérôme Josse, Marine Butin

SUMMARYStaphylococcus capitis is divided into two subspecies, S. capitis subsp. ureolyticus (renamed urealyticus in 1992; ATCC 49326) and S. capitis subsp. capitis (ATCC 27840), and fits with the archetype of clinically relevant coagulase-negative staphylococci (CoNS). S. capitis is a commensal bacterium of the skin in humans, which must be considered an opportunistic pathogen of interest particularly as soon as it is identified in a clinically relevant specimen from an immunocompromised patient. Several studies have highlighted the potential determinants underlying S. capitis pathogenicity, resistance profiles, and virulence factors. In addition, mobile genetic element acquisitions and mutations contribute to S. capitis genome adaptation to its environment. Over the past decades, antibiotic resistance has been identified for S. capitis in almost all the families of the currently available antibiotics and is related to the emergence of multidrug-resistant clones of high clinical significance. The present review summarizes the current knowledge concerning the taxonomic position of S. capitis among staphylococci, the involvement of this species in human colonization and diseases, the virulence factors supporting its pathogenicity, and the phenotypic and genomic antimicrobial resistance profiles of this species.

摘要头状葡萄球菌分为两个亚种:头状葡萄球菌尿解亚种(1992 年更名为尿解葡萄球菌;ATCC 49326)和头状葡萄球菌头状亚种(ATCC 27840),符合临床相关凝固酶阴性葡萄球菌(CoNS)的原型。毛囊炎葡萄球菌是人类皮肤的共生细菌,一旦在免疫力低下患者的临床相关标本中发现这种细菌,就必须将其视为机会性病原体。一些研究强调了毛囊虫致病性、抗药性特征和毒力因子的潜在决定因素。此外,移动遗传因子的获得和突变也有助于毛滴虫基因组对环境的适应。在过去的几十年中,已发现毛滴虫对几乎所有目前可用的抗生素家族都具有抗药性,这与具有高度临床意义的多重耐药克隆的出现有关。本综述总结了当前关于头孢霉菌在葡萄球菌中的分类地位、该菌种在人类定植和疾病中的参与、支持其致病性的毒力因素以及该菌种的表型和基因组抗菌药耐药性概况的知识。
{"title":"<i>Staphylococcus capitis</i>: insights into epidemiology, virulence, and antimicrobial resistance of a clinically relevant bacterial species.","authors":"Deborah M Crepin, Marie Chavignon, Paul O Verhoeven, Frédéric Laurent, Jérôme Josse, Marine Butin","doi":"10.1128/cmr.00118-23","DOIUrl":"10.1128/cmr.00118-23","url":null,"abstract":"<p><p>SUMMARY<i>Staphylococcus capitis</i> is divided into two subspecies, <i>S. capitis</i> subsp. <i>ureolyticus</i> (renamed <i>urealyticus</i> in 1992; ATCC 49326) and <i>S. capitis</i> subsp. <i>capitis</i> (ATCC 27840), and fits with the archetype of clinically relevant coagulase-negative staphylococci (CoNS). <i>S. capitis</i> is a commensal bacterium of the skin in humans, which must be considered an opportunistic pathogen of interest particularly as soon as it is identified in a clinically relevant specimen from an immunocompromised patient. Several studies have highlighted the potential determinants underlying <i>S. capitis</i> pathogenicity, resistance profiles, and virulence factors. In addition, mobile genetic element acquisitions and mutations contribute to <i>S. capitis</i> genome adaptation to its environment. Over the past decades, antibiotic resistance has been identified for <i>S. capitis</i> in almost all the families of the currently available antibiotics and is related to the emergence of multidrug-resistant clones of high clinical significance. The present review summarizes the current knowledge concerning the taxonomic position of <i>S. capitis</i> among staphylococci, the involvement of this species in human colonization and diseases, the virulence factors supporting its pathogenicity, and the phenotypic and genomic antimicrobial resistance profiles of this species.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections. 预防医疗相关细菌感染的疫苗和单克隆抗体。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-09-12 Epub Date: 2024-08-09 DOI: 10.1128/cmr.00160-22
Léo Sauvat, Paul O Verhoeven, Julie Gagnaire, Philippe Berthelot, Stéphane Paul, Elisabeth Botelho-Nevers, Amandine Gagneux-Brunon

SUMMARYHealthcare-associated infections (HAIs) represent a burden for public health with a high prevalence and high death rates associated with them. Pathogens with a high potential for antimicrobial resistance, such as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) and Clostridioides difficile, are responsible for most HAIs. Despite the implementation of infection prevention and control intervention, globally, HAIs prevalence is stable and they are mainly due to endogenous pathogens. It is undeniable that complementary to infection prevention and control measures, prophylactic approaches by active or passive immunization are needed. Specific groups at-risk (elderly people, chronic condition as immunocompromised) and also healthcare workers are key targets. Medical procedures and specific interventions are known to be at risk of HAIs, in addition to hospital environmental exposure. Vaccines or monoclonal antibodies can be seen as attractive preventive approaches for HAIs. In this review, we present an overview of the vaccines and monoclonal antibodies in clinical development for prevention of the major bacterial HAIs pathogens. Based on the current state of knowledge, we look at the challenges and future perspectives to improve prevention by these means.

摘要医疗相关感染(HAIs)是公共卫生的一个负担,其发病率和死亡率都很高。抗菌药耐药性潜力高的病原体,如 ESKAPE 病原体(粪肠球菌、金黄色葡萄球菌、肺炎克雷伯氏菌、鲍曼不动杆菌、铜绿假单胞菌和肠杆菌)和难辨梭状芽胞杆菌是大多数 HAIs 的罪魁祸首。尽管实施了感染预防和控制干预措施,但在全球范围内,HAIs 的发病率仍保持稳定,而且主要是由内源性病原体引起的。不可否认,除了感染预防和控制措施外,还需要采取主动或被动免疫的预防方法。高危人群(老年人、免疫力低下的慢性病患者)和医护人员是重点关注对象。除了接触医院环境外,医疗程序和特定干预措施也有可能导致 HAIs。疫苗或单克隆抗体可被视为具有吸引力的预防 HAIs 的方法。在这篇综述中,我们概述了为预防主要细菌性 HAIs 病原体而进行临床开发的疫苗和单克隆抗体。基于目前的知识水平,我们探讨了通过这些方法改善预防效果所面临的挑战和未来前景。
{"title":"Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections.","authors":"Léo Sauvat, Paul O Verhoeven, Julie Gagnaire, Philippe Berthelot, Stéphane Paul, Elisabeth Botelho-Nevers, Amandine Gagneux-Brunon","doi":"10.1128/cmr.00160-22","DOIUrl":"10.1128/cmr.00160-22","url":null,"abstract":"<p><p>SUMMARYHealthcare-associated infections (HAIs) represent a burden for public health with a high prevalence and high death rates associated with them. Pathogens with a high potential for antimicrobial resistance, such as ESKAPE pathogens (<i><u>E</u>nterococcus faecium, <u>S</u>taphylococcus aureus, <u>K</u>lebsiella pneumoniae, <u>A</u>cinetobacter baumannii, <u>P</u>seudomonas aeruginosa,</i> and <i><u>E</u>nterobacter species</i>) and <i>Clostridioides difficile</i>, are responsible for most HAIs. Despite the implementation of infection prevention and control intervention, globally, HAIs prevalence is stable and they are mainly due to endogenous pathogens. It is undeniable that complementary to infection prevention and control measures, prophylactic approaches by active or passive immunization are needed. Specific groups at-risk (elderly people, chronic condition as immunocompromised) and also healthcare workers are key targets. Medical procedures and specific interventions are known to be at risk of HAIs, in addition to hospital environmental exposure. Vaccines or monoclonal antibodies can be seen as attractive preventive approaches for HAIs. In this review, we present an overview of the vaccines and monoclonal antibodies in clinical development for prevention of the major bacterial HAIs pathogens. Based on the current state of knowledge, we look at the challenges and future perspectives to improve prevention by these means.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis. 临床微生物实验室实用指南》:处理囊性纤维化患者呼吸道样本的最新指南。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-09-12 Epub Date: 2024-08-19 DOI: 10.1128/cmr.00215-21
Lisa Saiman, Valerie Waters, John J LiPuma, Lucas R Hoffman, Kevin Alby, Sean X Zhang, Yvonne C Yau, Damian G Downey, Isabelle Sermet-Gaudelus, Jean-Philippe Bouchara, Timothy J Kidd, Scott C Bell, A Whitney Brown

SUMMARYThis guidance presents recommendations for clinical microbiology laboratories for processing respiratory samples from people with cystic fibrosis (pwCF). Appropriate processing of respiratory samples is crucial to detect bacterial and fungal pathogens, guide treatment, monitor the epidemiology of cystic fibrosis (CF) pathogens, and assess therapeutic interventions. Thanks to CF transmembrane conductance regulator modulator therapy, the health of pwCF has improved, but as a result, fewer pwCF spontaneously expectorate sputum. Thus, the collection of sputum samples has decreased, while the collection of other types of respiratory samples such as oropharyngeal and bronchoalveolar lavage samples has increased. To optimize the detection of microorganisms, including Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, and Burkholderia cepacia complex; other less common non-lactose fermenting Gram-negative bacilli, e.g., Stenotrophomonas maltophilia, Inquilinus, Achromobacter, Ralstonia, and Pandoraea species; and yeasts and filamentous fungi, non-selective and selective culture media are recommended for all types of respiratory samples, including samples obtained from pwCF after lung transplantation. There are no consensus recommendations for laboratory practices to detect, characterize, and report small colony variants (SCVs) of S. aureus, although studies are ongoing to address the potential clinical impact of SCVs. Accurate identification of less common Gram-negative bacilli, e.g., S. maltophilia, Inquilinus, Achromobacter, Ralstonia, and Pandoraea species, as well as yeasts and filamentous fungi, is recommended to understand their epidemiology and clinical importance in pwCF. However, conventional biochemical tests and automated platforms may not accurately identify CF pathogens. MALDI-TOF MS provides excellent genus-level identification, but databases may lack representation of CF pathogens to the species-level. Thus, DNA sequence analysis should be routinely available to laboratories for selected clinical circumstances. Antimicrobial susceptibility testing (AST) is not recommended for every routine surveillance culture obtained from pwCF, although selective AST may be helpful, e.g., for unusual pathogens or exacerbations unresponsive to initial therapy. While this guidance reflects current care paradigms for pwCF, recommendations will continue to evolve as CF research expands the evidence base for laboratory practices.

摘要 本指南提出了临床微生物实验室处理囊性纤维化患者 (pwCF) 呼吸道样本的建议。适当处理呼吸道样本对于检测细菌和真菌病原体、指导治疗、监测囊性纤维化 (CF) 病原体的流行病学以及评估治疗干预措施至关重要。得益于囊性纤维化跨膜传导调节剂的治疗,囊性纤维化患者的健康状况有所改善,但自发排痰的囊性纤维化患者却越来越少。因此,痰样本的采集量减少了,而口咽和支气管肺泡灌洗液样本等其他类型呼吸道样本的采集量却增加了。为了优化微生物的检测,包括铜绿假单胞菌、金黄色葡萄球菌、流感嗜血杆菌、伯克霍尔德氏菌头孢菌素复合体,以及其他不常见的非乳糖发酵革兰氏阴性杆菌,如嗜血杆菌、恶性链球菌等、对于所有类型的呼吸道样本,包括肺移植后从 pwCF 获得的样本,建议使用非选择性和选择性培养基来培养酵母菌和丝状真菌。对于检测、鉴定和报告金黄色葡萄球菌小菌落变异(SCVs)的实验室方法,目前还没有达成共识的建议,尽管针对 SCVs 潜在临床影响的研究正在进行中。建议准确鉴定不常见的革兰氏阴性杆菌,例如:S. maltopholia、Inquilinus、Achromobacter、Ralstonia 和 Pandoraea 菌种,以及酵母菌和丝状真菌,以了解它们的流行病学和临床影响。
{"title":"Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.","authors":"Lisa Saiman, Valerie Waters, John J LiPuma, Lucas R Hoffman, Kevin Alby, Sean X Zhang, Yvonne C Yau, Damian G Downey, Isabelle Sermet-Gaudelus, Jean-Philippe Bouchara, Timothy J Kidd, Scott C Bell, A Whitney Brown","doi":"10.1128/cmr.00215-21","DOIUrl":"10.1128/cmr.00215-21","url":null,"abstract":"<p><p>SUMMARYThis guidance presents recommendations for clinical microbiology laboratories for processing respiratory samples from people with cystic fibrosis (pwCF). Appropriate processing of respiratory samples is crucial to detect bacterial and fungal pathogens, guide treatment, monitor the epidemiology of cystic fibrosis (CF) pathogens, and assess therapeutic interventions. Thanks to CF transmembrane conductance regulator modulator therapy, the health of pwCF has improved, but as a result, fewer pwCF spontaneously expectorate sputum. Thus, the collection of sputum samples has decreased, while the collection of other types of respiratory samples such as oropharyngeal and bronchoalveolar lavage samples has increased. To optimize the detection of microorganisms, including <i>Pseudomonas aeruginosa</i>, <i>Staphylococcus aureus</i>, <i>Haemophilus influenzae</i>, and <i>Burkholderia cepacia</i> complex; other less common non-lactose fermenting Gram-negative bacilli, e.g., <i>Stenotrophomonas maltophilia</i>, <i>Inquilinus</i>, <i>Achromobacter</i>, <i>Ralstonia</i>, and <i>Pandoraea</i> species; and yeasts and filamentous fungi, non-selective and selective culture media are recommended for all types of respiratory samples, including samples obtained from pwCF after lung transplantation. There are no consensus recommendations for laboratory practices to detect, characterize, and report small colony variants (SCVs) of <i>S. aureus</i>, although studies are ongoing to address the potential clinical impact of SCVs. Accurate identification of less common Gram-negative bacilli, e.g., <i>S. maltophilia</i>, <i>Inquilinus</i>, <i>Achromobacter</i>, <i>Ralstonia</i>, and <i>Pandoraea</i> species, as well as yeasts and filamentous fungi, is recommended to understand their epidemiology and clinical importance in pwCF. However, conventional biochemical tests and automated platforms may not accurately identify CF pathogens. MALDI-TOF MS provides excellent genus-level identification, but databases may lack representation of CF pathogens to the species-level. Thus, DNA sequence analysis should be routinely available to laboratories for selected clinical circumstances. Antimicrobial susceptibility testing (AST) is not recommended for every routine surveillance culture obtained from pwCF, although selective AST may be helpful, e.g., for unusual pathogens or exacerbations unresponsive to initial therapy. While this guidance reflects current care paradigms for pwCF, recommendations will continue to evolve as CF research expands the evidence base for laboratory practices.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The emerging challenge of Enterococcus faecalis endocarditis after transcatheter aortic valve implantation: time for innovative treatment approaches. 经导管主动脉瓣植入术后新出现的粪肠球菌心内膜炎挑战:创新治疗方法的时机已到。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-09-05 DOI: 10.1128/cmr.00168-23
Jaclyn A Cusumano, Andreas P Kalogeropoulos, Mathieu Le Provost, Nicolas R Gallo, Steven M Levine, Thomas Inzana, Aikaterini Papamanoli

SUMMARYInfective endocarditis (IE) is a life-threatening infection that has nearly doubled in prevalence over the last two decades due to the increase in implantable cardiac devices. Transcatheter aortic valve implantation (TAVI) is currently one of the most common cardiac procedures. TAVI usage continues to exponentially rise, inevitability increasing TAVI-IE. Patients with TAVI are frequently nonsurgical candidates, and TAVI-IE 1-year mortality rates can be as high as 74% without valve or bacterial biofilm removal. Enterococcus faecalis, a historically less common IE pathogen, is the primary cause of TAVI-IE. Treatment options are limited due to enterococcal intrinsic resistance and biofilm formation. Novel approaches are warranted to tackle current therapeutic gaps. We describe the existing challenges in treating TAVI-IE and how available treatment discovery approaches can be combined with an in silico "Living Heart" model to create solutions for the future.

摘要感染性心内膜炎(IE)是一种威胁生命的感染,由于植入式心脏设备的增加,其发病率在过去二十年中几乎翻了一番。经导管主动脉瓣植入术(TAVI)是目前最常见的心脏手术之一。经导管主动脉瓣植入术的使用率继续呈指数增长,不可避免地增加了经导管主动脉瓣植入术的创伤。TAVI 患者通常都是非手术候选者,如果不清除瓣膜或细菌生物膜,TAVI-IE 1 年死亡率可高达 74%。粪肠球菌是一种历史上较少见的 IE 病原,是导致 TAVI-IE 的主要原因。由于肠球菌的内在耐药性和生物膜的形成,治疗方案十分有限。需要采用新方法来解决目前的治疗空白。我们介绍了治疗 TAVI-IE 的现有挑战,以及如何将现有的治疗发现方法与硅学 "活体心脏 "模型相结合,为未来创造解决方案。
{"title":"The emerging challenge of <i>Enterococcus faecalis</i> endocarditis after transcatheter aortic valve implantation: time for innovative treatment approaches.","authors":"Jaclyn A Cusumano, Andreas P Kalogeropoulos, Mathieu Le Provost, Nicolas R Gallo, Steven M Levine, Thomas Inzana, Aikaterini Papamanoli","doi":"10.1128/cmr.00168-23","DOIUrl":"10.1128/cmr.00168-23","url":null,"abstract":"<p><p>SUMMARYInfective endocarditis (IE) is a life-threatening infection that has nearly doubled in prevalence over the last two decades due to the increase in implantable cardiac devices. Transcatheter aortic valve implantation (TAVI) is currently one of the most common cardiac procedures. TAVI usage continues to exponentially rise, inevitability increasing TAVI-IE. Patients with TAVI are frequently nonsurgical candidates, and TAVI-IE 1-year mortality rates can be as high as 74% without valve or bacterial biofilm removal. <i>Enterococcus faecalis,</i> a historically less common IE pathogen, is the primary cause of TAVI-IE. Treatment options are limited due to enterococcal intrinsic resistance and biofilm formation. Novel approaches are warranted to tackle current therapeutic gaps. We describe the existing challenges in treating TAVI-IE and how available treatment discovery approaches can be combined with an <i>in silico</i> \"Living Heart\" model to create solutions for the future.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities 肠道微生物群在导致体重失调和相关并发症方面的作用
IF 36.8 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-06-28 DOI: 10.1128/cmr.00045-23
Matthias Van HulAudrey M. NeyrinckAmandine EverardAnne AbotLaure B. BindelsNathalie M. DelzenneClaude KnaufPatrice D. Cani1UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute (LDRI), Metabolism and Nutrition Research Group (MNUT), Brussels, Belgium2Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), WELBIO department, WEL Research Institute, Wavre, Belgium3NeuroMicrobiota, International Research Program (IRP) INSERM/UCLouvain, France/Belgium4Enterosys SAS, Labège, France5INSERM U1220, Institut de Recherche en Santé Digestive (IRSD), Université Paul Sabatier, Toulouse III, CHU Purpan, Toulouse, France6UCLouvain, Université catholique de Louvain, Institute of Experimental and Clinical Research (IREC), Brussels, BelgiumChristopher Staley
Clinical Microbiology Reviews, Ahead of Print.
临床微生物学评论》,提前出版。
{"title":"Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities","authors":"Matthias Van HulAudrey M. NeyrinckAmandine EverardAnne AbotLaure B. BindelsNathalie M. DelzenneClaude KnaufPatrice D. Cani1UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute (LDRI), Metabolism and Nutrition Research Group (MNUT), Brussels, Belgium2Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), WELBIO department, WEL Research Institute, Wavre, Belgium3NeuroMicrobiota, International Research Program (IRP) INSERM/UCLouvain, France/Belgium4Enterosys SAS, Labège, France5INSERM U1220, Institut de Recherche en Santé Digestive (IRSD), Université Paul Sabatier, Toulouse III, CHU Purpan, Toulouse, France6UCLouvain, Université catholique de Louvain, Institute of Experimental and Clinical Research (IREC), Brussels, BelgiumChristopher Staley","doi":"10.1128/cmr.00045-23","DOIUrl":"https://doi.org/10.1128/cmr.00045-23","url":null,"abstract":"Clinical Microbiology Reviews, Ahead of Print. <br/>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":36.8,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141462951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. 艰难梭菌感染:历史、流行病学、风险因素、预防、临床表现、治疗和未来选择。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-06-13 Epub Date: 2024-02-29 DOI: 10.1128/cmr.00135-23
Stefano Di Bella, Gianfranco Sanson, Jacopo Monticelli, Verena Zerbato, Luigi Principe, Mauro Giuffrè, Giuseppe Pipitone, Roberto Luzzati

SUMMARYClostridioides difficile infection (CDI) is one of the major issues in nosocomial infections. This bacterium is constantly evolving and poses complex challenges for clinicians, often encountered in real-life scenarios. In the face of CDI, we are increasingly equipped with new therapeutic strategies, such as monoclonal antibodies and live biotherapeutic products, which need to be thoroughly understood to fully harness their benefits. Moreover, interesting options are currently under study for the future, including bacteriophages, vaccines, and antibiotic inhibitors. Surveillance and prevention strategies continue to play a pivotal role in limiting the spread of the infection. In this review, we aim to provide the reader with a comprehensive overview of epidemiological aspects, predisposing factors, clinical manifestations, diagnostic tools, and current and future prophylactic and therapeutic options for C. difficile infection.

摘要 艰难梭状芽孢杆菌感染(CDI)是医院内感染的主要问题之一。这种细菌不断演变,给临床医生带来了复杂的挑战,在现实生活中经常会遇到。面对 CDI,我们越来越多地采用了新的治疗策略,如单克隆抗体和活体生物治疗产品。此外,目前正在研究未来的有趣方案,包括噬菌体、疫苗和抗生素抑制剂。监测和预防策略在限制感染传播方面仍起着关键作用。在这篇综述中,我们旨在向读者全面介绍艰难梭菌感染的流行病学、易感性因素、临床表现、诊断工具以及当前和未来的预防和治疗方案。
{"title":"<i>Clostridioides difficile</i> infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.","authors":"Stefano Di Bella, Gianfranco Sanson, Jacopo Monticelli, Verena Zerbato, Luigi Principe, Mauro Giuffrè, Giuseppe Pipitone, Roberto Luzzati","doi":"10.1128/cmr.00135-23","DOIUrl":"10.1128/cmr.00135-23","url":null,"abstract":"<p><p>SUMMARY<i>Clostridioides difficile</i> infection (CDI) is one of the major issues in nosocomial infections. This bacterium is constantly evolving and poses complex challenges for clinicians, often encountered in real-life scenarios. In the face of CDI, we are increasingly equipped with new therapeutic strategies, such as monoclonal antibodies and live biotherapeutic products, which need to be thoroughly understood to fully harness their benefits. Moreover, interesting options are currently under study for the future, including bacteriophages, vaccines, and antibiotic inhibitors. Surveillance and prevention strategies continue to play a pivotal role in limiting the spread of the infection. In this review, we aim to provide the reader with a comprehensive overview of epidemiological aspects, predisposing factors, clinical manifestations, diagnostic tools, and current and future prophylactic and therapeutic options for <i>C. difficile</i> infection.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chagas disease in immunocompromised patients. 免疫力低下患者的南美锥虫病。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-06-13 Epub Date: 2024-03-28 DOI: 10.1128/cmr.00099-23
Eva H Clark, Louisa A Messenger, Jeffrey D Whitman, Caryn Bern

SUMMARYAs Chagas disease remains prevalent in the Americas, it is important that healthcare professionals and researchers are aware of the screening, diagnosis, monitoring, and treatment recommendations for the populations of patients they care for and study. Management of Trypanosoma cruzi infection in immunocompromised hosts is challenging, particularly because, regardless of antitrypanosomal treatment status, immunocompromised patients with Chagas disease are at risk for T. cruzi reactivation, which can be lethal. Evidence-based practices to prevent and manage T. cruzi reactivation vary depending on the type of immunocompromise. Here, we review available data describing Chagas disease epidemiology, testing, and management practices for various populations of immunocompromised individuals, including people with HIV and patients undergoing solid organ and hematopoietic stem cell transplantation.

摘要随着南美锥虫病在美洲的流行,医疗保健专业人员和研究人员必须了解他们所护理和研究的患者群体的筛查、诊断、监测和治疗建议。对免疫力低下的宿主进行克鲁兹锥虫感染管理具有挑战性,尤其是因为无论是否接受过抗锥虫治疗,免疫力低下的南美锥虫病患者都面临着克鲁兹锥虫再活化的风险,而这种再活化可能是致命的。预防和控制 T. cruzi 再活化的循证实践因免疫力低下的类型而异。在此,我们回顾了现有的数据,描述了恰加斯病的流行病学、检测和不同免疫力低下人群的管理方法,包括艾滋病病毒感染者和接受实体器官及造血干细胞移植的患者。
{"title":"Chagas disease in immunocompromised patients.","authors":"Eva H Clark, Louisa A Messenger, Jeffrey D Whitman, Caryn Bern","doi":"10.1128/cmr.00099-23","DOIUrl":"10.1128/cmr.00099-23","url":null,"abstract":"<p><p>SUMMARYAs Chagas disease remains prevalent in the Americas, it is important that healthcare professionals and researchers are aware of the screening, diagnosis, monitoring, and treatment recommendations for the populations of patients they care for and study. Management of <i>Trypanosoma cruzi</i> infection in immunocompromised hosts is challenging, particularly because, regardless of antitrypanosomal treatment status, immunocompromised patients with Chagas disease are at risk for <i>T. cruzi</i> reactivation, which can be lethal. Evidence-based practices to prevent and manage <i>T. cruzi</i> reactivation vary depending on the type of immunocompromise. Here, we review available data describing Chagas disease epidemiology, testing, and management practices for various populations of immunocompromised individuals, including people with HIV and patients undergoing solid organ and hematopoietic stem cell transplantation.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections. Scedosporiosis 和 lomentosporiosis:从现代角度看这些难以治疗的罕见霉菌感染。
IF 19 1区 医学 Q1 MICROBIOLOGY Pub Date : 2024-06-13 Epub Date: 2024-03-29 DOI: 10.1128/cmr.00004-23
Chin Fen Neoh, Sharon C-A Chen, Fanny Lanternier, Shio Yen Tio, Catriona L Halliday, Sarah E Kidd, David C M Kong, Wieland Meyer, Martin Hoenigl, Monica A Slavin

SUMMARYAlthough Scedosporium species and Lomentospora prolificans are uncommon causes of invasive fungal diseases (IFDs), these infections are associated with high mortality and are costly to treat with a limited armamentarium of antifungal drugs. In light of recent advances, including in the area of new antifungals, the present review provides a timely and updated overview of these IFDs, with a focus on the taxonomy, clinical epidemiology, pathogenesis and host immune response, disease manifestations, diagnosis, antifungal susceptibility, and treatment. An expansion of hosts at risk for these difficult-to-treat infections has emerged over the last two decades given the increased use of, and broader population treated with, immunomodulatory and targeted molecular agents as well as wider adoption of antifungal prophylaxis. Clinical presentations differ not only between genera but also across the different Scedosporium species. L. prolificans is intrinsically resistant to most currently available antifungal agents, and the prognosis of immunocompromised patients with lomentosporiosis is poor. Development of, and improved access to, diagnostic modalities for early detection of these rare mold infections is paramount for timely targeted antifungal therapy and surgery if indicated. New antifungal agents (e.g., olorofim, fosmanogepix) with novel mechanisms of action and less cross-resistance to existing classes, availability of formulations for oral administration, and fewer drug-drug interactions are now in late-stage clinical trials, and soon, could extend options to treat scedosporiosis/lomentosporiosis. Much work remains to increase our understanding of these infections, especially in the pediatric setting. Knowledge gaps for future research are highlighted in the review.

摘要虽然头孢菌属(Scedosporium species)和多孔菌属(Lomentospora prolificans)是侵袭性真菌病(IFDs)的不常见病因,但这些感染的死亡率很高,而且用有限的抗真菌药物进行治疗的成本很高。鉴于最近在新型抗真菌药物等方面取得的进展,本综述对这些侵袭性真菌病进行了及时和最新的概述,重点介绍了其分类、临床流行病学、发病机制和宿主免疫反应、疾病表现、诊断、抗真菌药物敏感性和治疗。在过去二十年中,随着免疫调节药物和靶向分子药物的使用增多,接受治疗的人群扩大,以及抗真菌预防措施的广泛采用,面临这些难以治疗的感染风险的宿主也随之增加。临床表现不仅在不同属之间存在差异,而且在不同种的Scedosporium之间也存在差异。多孢子菌(L. prolificans)对大多数现有的抗真菌药物具有内在抗药性,免疫力低下的洛美多孢子菌病患者预后很差。开发和改进诊断方法以早期发现这些罕见的霉菌感染,对于及时进行有针对性的抗真菌治疗和手术(如有必要)至关重要。新的抗真菌药物(如奥洛芬、福斯马诺吉匹克)具有新的作用机制,与现有药物的交叉耐药性较少,可用于口服,药物间相互作用较小,目前已进入后期临床试验阶段,很快就能扩大治疗头孢孢子菌病/洛美多孢子菌病的选择范围。要进一步了解这些感染,尤其是儿科感染,还有很多工作要做。综述中强调了未来研究的知识缺口。
{"title":"Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.","authors":"Chin Fen Neoh, Sharon C-A Chen, Fanny Lanternier, Shio Yen Tio, Catriona L Halliday, Sarah E Kidd, David C M Kong, Wieland Meyer, Martin Hoenigl, Monica A Slavin","doi":"10.1128/cmr.00004-23","DOIUrl":"10.1128/cmr.00004-23","url":null,"abstract":"<p><p>SUMMARYAlthough <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> are uncommon causes of invasive fungal diseases (IFDs), these infections are associated with high mortality and are costly to treat with a limited armamentarium of antifungal drugs. In light of recent advances, including in the area of new antifungals, the present review provides a timely and updated overview of these IFDs, with a focus on the taxonomy, clinical epidemiology, pathogenesis and host immune response, disease manifestations, diagnosis, antifungal susceptibility, and treatment. An expansion of hosts at risk for these difficult-to-treat infections has emerged over the last two decades given the increased use of, and broader population treated with, immunomodulatory and targeted molecular agents as well as wider adoption of antifungal prophylaxis. Clinical presentations differ not only between genera but also across the different <i>Scedosporium</i> species. <i>L. prolificans</i> is intrinsically resistant to most currently available antifungal agents, and the prognosis of immunocompromised patients with lomentosporiosis is poor. Development of, and improved access to, diagnostic modalities for early detection of these rare mold infections is paramount for timely targeted antifungal therapy and surgery if indicated. New antifungal agents (e.g., olorofim, fosmanogepix) with novel mechanisms of action and less cross-resistance to existing classes, availability of formulations for oral administration, and fewer drug-drug interactions are now in late-stage clinical trials, and soon, could extend options to treat scedosporiosis/lomentosporiosis. Much work remains to increase our understanding of these infections, especially in the pediatric setting. Knowledge gaps for future research are highlighted in the review.</p>","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140317920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Microbiology Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1